PharmGKB: A worldwide resource for pharmacogenomic information
暂无分享,去创建一个
Julia M. Barbarino | R. Altman | M. Whirl‐Carrillo | T. Klein | J. Barbarino | Michelle Whirl‐Carrillo
[1] G. Tucker,et al. Principles of pharmacokinetics. , 1979, Ciba Foundation symposium.
[2] R. Lewontin,et al. Somatic versus germinal mutation , 2000 .
[3] Joshua M. Stuart,et al. Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.
[4] Roger L Albin,et al. Genomic Medicine [4] (multiple letters) , 2003 .
[5] Alison Abbott,et al. Special section on human genetics: With your genes? Take one of these, three times a day , 2003, Nature.
[6] R. Weinshilboum,et al. Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.
[7] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.
[8] Russ B. Altman,et al. Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.
[9] Gideon Koren,et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. , 2010, Thyroid : official journal of the American Thyroid Association.
[10] R. Altman,et al. Very important pharmacogene summary: thiopurine S-methyltransferase. , 2010, Pharmacogenetics and genomics.
[11] R. Altman,et al. Thiopurine pathway. , 2010, Pharmacogenetics and genomics.
[12] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.
[13] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[14] Michelle Whirl-Carrillo,et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. , 2011, Biomarkers in medicine.
[15] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[16] S. Scott,et al. Personalizing medicine with clinical pharmacogenetics , 2011, Genetics in Medicine.
[17] J. Gill,et al. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. , 2012, Human immunology.
[18] S. Mallal,et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.
[19] D. Margulies,et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01 an autoimmune model for HLA-associated drug hypersensitivity , 2012, AIDS.
[20] Russ B. Altman,et al. Chapter 7: Pharmacogenomics , 2012, PLoS Comput. Biol..
[21] J. McCluskey,et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.
[22] JAMA patient page. Genomic medicine. , 2013, JAMA.
[23] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[24] E. Gershon,et al. Ethical and public policy challenges for pharmacogenomics , 2014, Dialogues in clinical neuroscience.
[25] Teri E. Klein,et al. Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.
[26] T. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.
[27] R. Altman,et al. PharmGKB summary: abacavir pathway , 2014, Pharmacogenetics and genomics.
[28] Demetrius J Porche,et al. Precision Medicine Initiative , 2015, American journal of men's health.
[29] William E. Evans,et al. Pharmacogenomics in the clinic , 2015, Nature.
[30] Teri E Klein,et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.
[31] P. Campbell,et al. Somatic mutation in cancer and normal cells , 2015, Science.
[32] L. Dean. Mercaptopurine Therapy and TPMT Genotype , 2016 .
[33] Amanda K. Sarata,et al. The Precision Medicine Initiative , 2016 .
[34] R. Altman,et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems , 2017, Clinical pharmacology and therapeutics.
[35] Marylyn D. Ritchie,et al. PharmCAT: A Pharmacogenomics Clinical Annotation Tool , 2017, Clinical pharmacology and therapeutics.
[36] Marc S. Williams,et al. Pharmacogenomics , 2019, The Lancet.